Cargando…

Pharmacological Characterization of Toludesvenlafaxine as a Triple Reuptake Inhibitor

Toludesvenlafaxine hydrochloride dihydrate is a novel chemical entity and a potential triple monoamine reuptake inhibitor. This study characterized the in vitro triple reuptake inhibition activity, antidepressant-like activity in animals, and pharmacokinetic profiles in rats of toludesvenlafaxine. B...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Haibo, Wang, Wenyan, Sha, Chunjie, Guo, Wei, Li, Chunmei, Zhao, Fengjuan, Wang, Hongbo, Jiang, Wanglin, Tian, Jingwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476831/ https://www.ncbi.nlm.nih.gov/pubmed/34594228 http://dx.doi.org/10.3389/fphar.2021.741794

Ejemplares similares

The effect of triple reuptake inhibitor toludesvenlafaxine on neurological function in cerebral ischemic rats
por: Sun, Xiaohui, et al.
Publicado: (2023)

LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain
por: Li, Nannan, et al.
Publicado: (2019)

Epigenetic Mechanism of 5-HT/NE/DA Triple Reuptake Inhibitor on Adult Depression Susceptibility in Early Stress Mice
por: Meng, Ping, et al.
Publicado: (2022)

Subacute toxicity evaluations of LPM3480392 in rats, a full µ-opioid receptor biased agonist
por: Ye, Liang, et al.
Publicado: (2023)

Antidepressant-like Effects of LPM580153, A Novel Potent Triple Reuptake Inhibitor
por: Zhang, Fangxi, et al.
Publicado: (2016)

Pharmacological and toxicological studies of a novel goserelin acetate extended-release microspheres in rats
por: Yutong, Mao, et al.
Publicado: (2023)

LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer
por: Qiu, Jiahao, et al.
Publicado: (2022)

Pediatric Therapeutic Drug Monitoring for Selective Serotonin Reuptake Inhibitors
por: Strawn, Jeffrey R., et al.
Publicado: (2021)

Efficacy, Tolerability, and Safety of Toludesvenlafaxine for the Treatment of Major Depressive Disorder—A Narrative Review
por: Vasiliu, Octavian
Publicado: (2023)

Triple Reuptake Inhibitors: The Next Generation of Antidepressants
por: Marks, David M, et al.
Publicado: (2008)

Triple Reuptake Inhibitors: A Premise and Promise
por: Marks, David M., et al.
Publicado: (2008)

Pharmacological and Behavioral Characterization of D-473, an Orally Active Triple Reuptake Inhibitor Targeting Dopamine, Serotonin and Norepinephrine Transporters
por: Dutta, Aloke K., et al.
Publicado: (2014)

Selective Serotonin Reuptake Inhibitor Pharmacokinetics During Pregnancy: Clinical and Research Implications
por: Poweleit, Ethan A., et al.
Publicado: (2022)

Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19
por: Asadi Anar, Mahsa, et al.
Publicado: (2022)

Clinical pharmacology of serotonin selective reuptake inhibitors /
por: Preskorn, Sheldon
Publicado: (1996)

(+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia
por: Wang, Wenyan, et al.
Publicado: (2021)

Structural Requirements for Modulating 4-Benzylpiperidine Carboxamides from Serotonin/Norepinephrine Reuptake Inhibitors to Triple Reuptake Inhibitors
por: Paudel, Suresh, et al.
Publicado: (2021)

Differentiated HT22 cells as a novel model for in vitro screening of serotonin reuptake inhibitors
por: Lim, Juhee, et al.
Publicado: (2023)

Case-Control Study Examining the Association between Selective Serotonin Reuptake Inhibitors Use and Hepatocellular Carcinoma
por: Lai, Shih-Wei, et al.
Publicado: (2017)

Raltegravir Attenuates Experimental Pulmonary Fibrosis In Vitro and In Vivo
por: Zhang, Xue, et al.
Publicado: (2019)

Selective Serotonin Reuptake Inhibitor Antidepressant Treatment Discontinuation Syndrome: A Review of the Clinical Evidence and the Possible Mechanisms Involved
por: Renoir, Thibault
Publicado: (2013)

The Risk of Ventricular Dysrhythmia or Sudden Death in Patients Receiving Serotonin Reuptake Inhibitors With Methadone: A Population-Based Study
por: Antoniou, Tony, et al.
Publicado: (2022)

Difficulty in Repurposing Selective Serotonin Reuptake Inhibitors and Other Antidepressants with Functional Inhibition of Acid Sphingomyelinase in COVID-19 Infection
por: Le Corre, Pascal, et al.
Publicado: (2022)

Comparative efficacy and acceptability of selective serotonin reuptake inhibitor antidepressants for binge eating disorder: A network meta-analysis
por: Duan, Hanying, et al.
Publicado: (2022)

The phytochemical and pharmacological profile of taraxasterol
por: Jiao, Fengjuan, et al.
Publicado: (2022)

Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment
por: Wang, Yunjie, et al.
Publicado: (2023)

Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study
por: Jimenez-Solem, Espen, et al.
Publicado: (2012)

The impacts of the “4+7” pilot policy on the volume, expenditures, and daily cost of Serotonin-Specific Reuptake Inhibitors (SSRIs) antidepressants: A quasi-experimental study
por: Wen, Xiaotong, et al.
Publicado: (2022)

Glyceroglycolipids in marine algae: A review of their pharmacological activity
por: Guo, Sha-sha, et al.
Publicado: (2022)

The Modulatory Properties of Astragalus membranaceus Treatment on Triple-Negative Breast Cancer: An Integrated Pharmacological Method
por: Liu, Cun, et al.
Publicado: (2019)

Translating clinical notes into quantitative measures—a real-world observation on the response to cholinesterase inhibitors or selective serotonin reuptake inhibitors prescribed to outpatients with dementia using electronic medical records
por: Chotiyanonta, Jill S., et al.
Publicado: (2023)

Monoaminergic Antidepressants in the Relief of Pain: Potential Therapeutic Utility of Triple Reuptake Inhibitors (TRIs)
por: Hache, Guillaume, et al.
Publicado: (2011)

Exploring the molecular mechanism of Gan Shuang granules for the treatment of non-alcoholic steatohepatitis using network pharmacology, molecular docking, and experimental verification
por: Zhi, Guoguo, et al.
Publicado: (2023)

Duloxetine, a Balanced Serotonin-Norepinephrine Reuptake Inhibitor, Improves Painful Chemotherapy-Induced Peripheral Neuropathy by Inhibiting Activation of p38 MAPK and NF-κB
por: Meng, Jing, et al.
Publicado: (2019)

Combining fecal microbiome and metabolomics to reveal the disturbance of gut microbiota in liver injury and the therapeutic mechanism of shaoyao gancao decoction
por: Li, Jingwei, et al.
Publicado: (2022)

Pharmacological Characterization of the Microsomal Prostaglandin E(2) Synthase-1 Inhibitor AF3485 In Vitro and In Vivo
por: Di Francesco, Luigia, et al.
Publicado: (2020)

Network pharmacology, molecular docking, and experimental validation to explore the potential mechanism of Long Mu Qing Xin mixture for the treatment of attention deficit hyperactivity disorder
por: Li, Xuejun, et al.
Publicado: (2023)

Monoamine depletion by reuptake inhibitors
por: Hinz, Marty, et al.
Publicado: (2011)

Network Pharmacology-Based and Experimental Identification of the Effects of Paeoniflorin on Major Depressive Disorder
por: Zhang, Sha, et al.
Publicado: (2022)

Sentiment Analysis of Online Reviews for Selective Serotonin Reuptake Inhibitors and Serotonin–Norepinephrine Reuptake Inhibitors
por: Compagner, Chad, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g6pk7h6c6p1ti738v401ugi3j2